Domača stranBMY • SWX
add
Bristol-Myers Squibb Co
Prejšnji trg. dan.
42,54 CHF
Letni razpon
42,54 CHF - 44,50 CHF
Tržna kapitalizacija
127,01 mrd. USD
Povprečni obseg
17,00
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
NYSE
V novicah
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | dec. 2025info | Sprememba L/L |
|---|---|---|
Prihodek | 12,50 mrd. | 1,30 % |
Stroški poslovanja | 5,47 mrd. | −13,56 % |
Čisti dohodek | 1,09 mrd. | 1.409,72 % |
Čista dobičkovnost prihodkov | 8,69 | 1.398,28 % |
Earnings per share | 1,26 | −24,55 % |
EBITDA | 4,54 mrd. | −2,17 % |
Efektivna davčna stopnja | 26,12 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | dec. 2025info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 10,67 mrd. | −1,71 % |
Skupna sredstva | 90,04 mrd. | −2,77 % |
Skupne obveznosti | 71,53 mrd. | −6,14 % |
Celoten lastniški kapital | 18,51 mrd. | — |
Shares outstanding | 2,04 mrd. | — |
Razmerje P/B | 4,69 | — |
Donosnost sredstev | 9,42 % | — |
Donosnost kapitala | 13,01 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | dec. 2025info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 1,09 mrd. | 1.409,72 % |
Denar iz dejavnosti | 1,97 mrd. | −55,53 % |
Denar iz naložb | −1,46 mrd. | −643,88 % |
Denar iz financiranja | −6,03 mrd. | −267,17 % |
Neto sprememba denarnih sredstev | −5,51 mrd. | −324,45 % |
Prost denarni tok | 669,62 mio. | −84,21 % |
Vizitka
Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban for people with atrial fibrillation; nivolumab, used to treat certain types of cancer; lenalidomide, used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes; abatacept, used to treat autoimmune diseases such as rheumatoid arthritis; pomalidomide, an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma; ipilimumab, to treat cancer; and luspatercept for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. In 2024, 71% of the company's revenues came from the United States.
The company is ranked 94th on the Fortune 500 and 173rd on the Forbes Global 2000. Wikipedia
Generalni direktor
Datum ustanovitve
1887
Sedež organizacije
Spletno mesto
Zaposleni
32.500
